全文获取类型
| 收费全文 | 2370187篇 |
| 免费 | 199358篇 |
| 国内免费 | 5112篇 |
专业分类
| 耳鼻咽喉 | 34343篇 |
| 儿科学 | 72668篇 |
| 妇产科学 | 63045篇 |
| 基础医学 | 333541篇 |
| 口腔科学 | 67725篇 |
| 临床医学 | 216027篇 |
| 内科学 | 466143篇 |
| 皮肤病学 | 48017篇 |
| 神经病学 | 199865篇 |
| 特种医学 | 96300篇 |
| 外国民族医学 | 897篇 |
| 外科学 | 360502篇 |
| 综合类 | 58684篇 |
| 现状与发展 | 4篇 |
| 一般理论 | 978篇 |
| 预防医学 | 190100篇 |
| 眼科学 | 55758篇 |
| 药学 | 178440篇 |
| 20篇 | |
| 中国医学 | 5078篇 |
| 肿瘤学 | 126522篇 |
出版年
| 2018年 | 24656篇 |
| 2017年 | 19218篇 |
| 2016年 | 20946篇 |
| 2015年 | 23857篇 |
| 2014年 | 34245篇 |
| 2013年 | 51468篇 |
| 2012年 | 69773篇 |
| 2011年 | 73421篇 |
| 2010年 | 43277篇 |
| 2009年 | 41539篇 |
| 2008年 | 69445篇 |
| 2007年 | 73867篇 |
| 2006年 | 74700篇 |
| 2005年 | 72712篇 |
| 2004年 | 69783篇 |
| 2003年 | 67329篇 |
| 2002年 | 66450篇 |
| 2001年 | 112558篇 |
| 2000年 | 116493篇 |
| 1999年 | 97952篇 |
| 1998年 | 26392篇 |
| 1997年 | 23969篇 |
| 1996年 | 23875篇 |
| 1995年 | 24571篇 |
| 1994年 | 23124篇 |
| 1993年 | 21494篇 |
| 1992年 | 79332篇 |
| 1991年 | 76442篇 |
| 1990年 | 73593篇 |
| 1989年 | 70845篇 |
| 1988年 | 65817篇 |
| 1987年 | 64788篇 |
| 1986年 | 61319篇 |
| 1985年 | 58386篇 |
| 1984年 | 44159篇 |
| 1983年 | 37550篇 |
| 1982年 | 22803篇 |
| 1981年 | 20234篇 |
| 1979年 | 41227篇 |
| 1978年 | 28911篇 |
| 1977年 | 24246篇 |
| 1976年 | 22756篇 |
| 1975年 | 23906篇 |
| 1974年 | 29590篇 |
| 1973年 | 28011篇 |
| 1972年 | 26208篇 |
| 1971年 | 24143篇 |
| 1970年 | 22729篇 |
| 1969年 | 21070篇 |
| 1968年 | 19118篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
101.
Clinical and Translational Oncology - Breast cancer with positive hormone receptor (HR) and human epidermal growth factor receptor-2 (HER2) is a special subgroup with different clinical features... 相似文献
102.
103.
目的 研究长链非编码RNA (LncRNA) UCA1对肺癌细胞增殖、凋亡及放射敏感性影响及其机制。方法 运用qRT-PCR法检测肺癌细胞A549、H1299和人正常肺细胞HBE中UCA1、miR-513a-5p表达。将si-con组(转染si-con)、si-UCA1组(转染si-UCA1)、miR-513a-5p组(转染miR-513a-5p mimics)、miR-NC组(转染miR-NC)、IR+si-con组(转染si-con+照射)、IR+si-UCA1组(转染miR-NC+照射)、IR+miR-513a-5p组(转染miR-513a-5p mimics+照射)、IR+miR-NC组(转染miR-NC+照射)、IR+si-UCA1+anti-miR-513a-5p组(共转染si-UCA1和anti-miR-513a-5p+照射)均用脂质体法转染至A549、H1299细胞,然后部分组进行4Gy照射。MTT法检测各组细胞增殖,克隆形成实验检测细胞增敏比,流式细胞术检测各组细胞凋亡,双荧光素没报告基因检测实验检测各组细胞的荧光活性。结果 与HBE细胞相比,A549、H1299细胞中UCA1表达显著升高(P<0.05),miR-513a-5p表达显著降低(P<0.05)。抑制UCA1、过表达miR-513a-5p均可明显抑制A549、H1299细胞增殖、促进凋亡、提高放射敏感性(放射增敏比为1.897、2.146和1.615、1.872)。miR-513a-5p可抑制野生型UCA1细胞的荧光活性,且UCA1可负向调控miR-513a-5p的表达。抑制miR-513a-5p可逆转抑制UCA1对细胞的放射敏感性的增强作用。结论 抑制LncRNA UCA1可增强放射对肺癌细胞敏感性,其机制可能与靶向抑制miR-513a-5p有关。 相似文献
104.
105.
106.
107.
Malinda Itchins Brandon Lau Amanda L. Hudson Helen Westman Cathy Yi Xia Sarah A. Hayes Viive M. Howell Michael Rodriguez Wendy A. Cooper Heng Wei Michael Buckland Bob T. Li Mark Li Vivek Rathi Stephen B. Fox Anthony J. Gill Stephen J. Clarke Michael J. Boyer Nick Pavlakis 《The oncologist》2020,25(8):641-649
108.
109.
M.S. Iqbal G. Vashisht R. McMenemin P. Atherton F. McDonald T. Simmons A. Bradshaw J. Kovarik H. Turnbull L. Dodd P. Mulvenna A. Greystoke 《Clinical oncology (Royal College of Radiologists (Great Britain))》2019,31(2):e1-e10
Aims
Concomitant chemoradiation is the standard of care in patients with inoperable non-small cell lung cancer. The purpose of this study was to analyse the survival outcome and toxicity data of using hypofractionated chemoradiation.Materials and methods
One hundred patients were treated from June 2011 to November 2016. Treatment consisted of 55 Gy in 20 daily fractions concurrently with split-dose cisplatin vinorelbine chemotherapy over 4 weeks followed by two cycles of cisplatin vinorelbine only. Survival was estimated using Kaplan–Meier and Cox regression was carried out for known prognostic factors. A systematic search of literature was conducted using Medline, Embase and Cochrane databases and relevant references included.Results
In total, 97% of patients completed radiotherapy and 73% of patients completed all four cycles of chemotherapy. One patient died of a cardiac event during consolidative chemotherapy. There were two cases of grade 4 toxicities (one sepsis, one renal impairment). Grade 3 toxicities included nausea/vomiting (17%), oesophagitis (15%), infection with neutropenia (12%) and pneumonitis (4%). Clinical benefit was seen in 86%. Two-year progression-free survival and overall survival rates were 49% and 58%, respectively. The median progression-free survival and overall survival were 23.4 and 43.4 months, respectively. The only significant prognostic factor was the number of chemotherapy cycles received (P = 0.02). The systematic review identified 13 relevant studies; a variety of regimens were assessed with variable reporting of outcomes and toxicity but with overall an improvement in survival over time.Conclusion
Our experience compared with the original phase II trial showed improved treatment completion rates and survival with acceptable morbidity. With appropriate patient selection this regimen is an effective treatment option for locally advanced non-small cell lung cancer. This study helps to benchmark efficacy and toxicity rates while considering the addition of new agents to hypofractionated concurrent chemoradiotherapy. The agreement of a standard regimen for assessment in future trials would be beneficial. 相似文献110.
Marita Zimmermann Solomon J. Lubinga Reiner Banken David Rind Geri Cramer Patricia G. Synnott Richard H. Chapman Sonya Khan Josh Carlson 《Value in health》2019,22(2):161-167